Evidence map›Paper›PMID 29616325›Full record

ArticleLung2018

Correction to: Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.

Henning Gall, Jean-Luc Vachiéry, Nobuhiro Tanabe, Michael Halank, Mauricio Orozco-Levi, Lisa Mielniczuk, MiKyung Chang, Kai Vogtländer, Ekkehard Grünig

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Lung, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Henning GallDepartment of Internal Medicine, Justus-Liebig-University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Klinikstrasse 32, 35392, Giessen, Germany. Henning.Gall@innere.med.uni-giessen.de.ORCID http://orcid.org/0000-0001-7016-7373
Jean-Luc VachiéryDépartement de Cardiologie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Brussels, Belgium.
Nobuhiro TanabeDepartment of Respirology and Department of Advanced Medicine in Pulmonary Hypertension, Graduate School of Medicine, Chiba University, Chiba, Japan.
Michael HalankMedical Clinic 1/Pneumology, University Hospital Carl Gustav Carus, Dresden, Germany.
Mauricio Orozco-LeviHospital Internacional de Colombia, Fundación Cardiovascular de Colombia, Santander, Colombia.
Lisa MielniczukUniversity of Ottawa Heart Institute, Ottawa, ON, Canada.
MiKyung ChangBayer AG, Berlin, Germany.
Kai VogtländerBayer AG, Wuppertal, Germany.
Ekkehard GrünigCenter for Pulmonary Hypertension, Thorax Clinic at the University Hospital, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The original version of this article unfortunately contained a mistake. In the "Results" section, the percentage of patients with inoperable or persistent/recurrent CTEPH included in the study was reported as 85%. This has been corrected to 68% with this erratum.

Identifiers

PMID29616325
PMCPMC6828299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.